Background The inhibition of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP)
is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific …

Deficiency in either of the breast cancer susceptibility proteins BRCA1 or BRCA2 induces
profound cellular sensitivity to the inhibition of poly(ADP-ribose) polymerase (PARP) activity. …

An underlying hallmark of cancers is their genomic instability, which is associated with a
greater propensity to accumulate DNA damage. Historical treatment of cancer by radiotherapy …

Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone
receptor-positive breast cancers, no tailored therapy exists for hormone receptor- and …

Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-,
chemical-, or ionizing radiation-induced DNA damage and represents a new target for cancer …

Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted
agents approved for cancer therapy. Here, we focus on their molecular mechanism of …

Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient
tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-…

The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured
in pre-clinical models. We have created a large collection of breast cancer patient-derived …

The transforming proteins of the small DNA tumor viruses, simian virus 40 (SV40), adenovirus,
and human papillomavirus (HPV) target a number of identical cellular regulators whose …

Ataxia telangiectasia (AT) mutated (ATM) is critical for cell cycle checkpoints and DNA repair.
Thus, specific small molecule inhibitors targeting ATM could perhaps be developed into …